Head-to-head comparison between 68Ga-PSMA and 18F-FDG-PET/CT in lymphomas: a preliminary analysis
- PMID: 34366406
- DOI: 10.1097/MNM.0000000000001465
Head-to-head comparison between 68Ga-PSMA and 18F-FDG-PET/CT in lymphomas: a preliminary analysis
Abstract
Purpose: Isolated case reports mention the uptake of radiolabeled PSMA in lymphoma. However, it is not clear if the intensity of 68Ga-PSMA expression varies among different histological subtypes or if it correlates with 18F-FDG uptake. This study compared both tracers in patients with diverse lymphoma subtypes.
Methods: Ten patients with biopsy-proven-lymphoma underwent 18F-FDG and 68Ga-PSMA-PET/CT (maximum time interval: 6 days). Lymphoma subtypes included Hodgkin's lymphoma (HL, three patients) and aggressive and indolent non-Hodgkin's lymphoma (NHL, seven patients). The intensity of PSMA uptake was classified visually as low, intermediate, or high, using blood pool, liver and parotid gland uptake as references. Maximum standardized-uptake value (SUVmax) of each affected site was measured in both sets of images.
Results: FDG detected 59/59 involved sites in 10 patients and PSMA 47/59 sites in nine patients. PSMA uptake was generally low, regardless of the intensity of FDG uptake, but it was classified as intermediate in two patients. The median SUVmax varied from 2.0 (2.0-8.2) to 30.9 for FDG and from 1.7 (1.7-1.7) to 4.4 for PSMA, P < 0.0001. The primary lesion of one patient had a marked intralesional mismatch uptake pattern of the tracers, with areas of higher PSMA expression than FDG uptake, and vice-versa. A brain lesion was more easily identified with PSMA than with FDG images.
Conclusion: HL and several NHL subtypes may present PSMA uptake. The intensity of PSMA expression is generally lower than that of FDG uptake and seems to present less variation among the different histological subtypes of lymphomas.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Value of 18F-FDG PET/CT in discrimination between indolent and aggressive non-Hodgkin's lymphoma: A study of 328 patients.Hell J Nucl Med. 2018 Jan-Apr;21(1):7-14. doi: 10.1967/s002449910701. Epub 2018 Mar 20. Hell J Nucl Med. 2018. PMID: 29550841
-
Utility of 18F-fluorodeoxyglucose PET-CT scan in detecting bone marrow involvement in lymphoma.Indian J Med Res. 2021 May;154(5):691-698. doi: 10.4103/ijmr.IJMR_1420_19. Indian J Med Res. 2021. PMID: 35532587 Free PMC article.
-
The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.Hell J Nucl Med. 2013 Sep-Dec;16(3):230-6. doi: 10.1967/s0024499100091. Epub 2013 Oct 2. Hell J Nucl Med. 2013. PMID: 24137577 Review.
-
PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.Semin Nucl Med. 2018 Jan;48(1):37-49. doi: 10.1053/j.semnuclmed.2017.09.004. Epub 2017 Nov 6. Semin Nucl Med. 2018. PMID: 29195616 Review.
Cited by
-
The complementary role of PSMA expression and [18F]FDG PET/CT in predicting thyroid cancer outcome: from black and white to shades of gray, in the era of precision oncology.EJNMMI Res. 2023 Jun 1;13(1):54. doi: 10.1186/s13550-023-01004-2. EJNMMI Res. 2023. PMID: 37261582 Free PMC article.
-
Head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT in multiple myeloma.Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2432-2440. doi: 10.1007/s00259-023-06214-3. Epub 2023 Mar 29. Eur J Nucl Med Mol Imaging. 2023. PMID: 36988710
-
The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer-A Practical Clinical Review.Cancers (Basel). 2022 Jul 26;14(15):3638. doi: 10.3390/cancers14153638. Cancers (Basel). 2022. PMID: 35892897 Free PMC article. Review.
-
18F-Prostate-Specific Membrane Antigen and 18F-Fluorodeoxyglucose PET/CT Unmasked the Characteristics of Prostate Lymphoma: A Case Report and Literature Review.Front Med (Lausanne). 2022 Apr 6;9:842093. doi: 10.3389/fmed.2022.842093. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35463037 Free PMC article.
References
-
- Keidar Z, Gill R, Goshen E, Israel O, Davidson T, Morgulis M, et al. 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls. Cancer Imaging. 2018; 18:39.
-
- Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997; 3:81–85.
-
- Stoykow C, Huber-Schumacher S, Almanasreh N, Jilg C, Ruf J. Strong PSMA radioligand uptake by rectal carcinoma: who put the “S” in PSMA? Clin Nucl Med. 2017; 42:225–226.
-
- Sasikumar A, Joy A, Pillai MR, Nanabala R, Anees KM, Jayaprakash PG, et al. Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors-preliminary analysis. Clin Nucl Med. 2017; 42:e41–e48.
-
- Lawhn-Heath C, Flavell RR, Glastonbury C, Hope TA, Behr SC. Incidental detection of head and neck squamous cell carcinoma on 68Ga-PSMA-11 PET/CT. Clin Nucl Med. 2017; 42:e218–e220.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
